# Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure

> **NCT04396899** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Medical Center Goettingen** · enrollment: 53 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **BIOLOGICAL:** EHM implantation

## Key facts

- **NCT ID:** NCT04396899
- **Lead sponsor:** University Medical Center Goettingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-03
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04396899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04396899, "Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04396899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*